{"schema_version":"secwatch.filing_event.v1","accession":"0001553350-21-000747","form_type":"8-K","ticker":"PDEX","cik":"0000788920","company_name":"PRO DEX INC","filed_at":"2021-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.762612+00:00","generated_at":"2026-06-29T07:42:21.813369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pro-Dex Q4 revenue falls 15% YoY; full-year sales up 9%","bullets":["Q4 net sales $9.4M (-15% YoY); net income $0.9M ($0.22 diluted EPS) vs $2.5M ($0.64) prior year.","FY2021 net sales $38.0M (+9% YoY); net income $4.5M ($1.13 EPS) down from $6.1M ($1.50).","Operating expenses up 49% to $9.1M, driven by increased R&D ($2.1M) and stock compensation ($615K).","R&D pipeline: ENT Shaver launches Q4 2021 (est. $1M annual rev); Vital Ventilator targets Q1 2022 ($1.5M est.).","COVID-19 caused under-absorbed manufacturing costs; supply chain delays ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001553350-21-000747","json":"https://secwatch.observer/filing/0001553350-21-000747.json","markdown":"https://secwatch.observer/filing/0001553350-21-000747.md","text":"https://secwatch.observer/filing/0001553350-21-000747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/788920/000155335021000747/0001553350-21-000747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/788920/000155335021000747/pdex_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T07:42:21.813369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}